CSL abandons $3.1 billion acquisition offer for Talecris

06/9/2009 | NYTimes.com

Australian biotech company CSL dropped its $3.1 billion bid to take over Talecris Biotherapeutics because the Federal Trade Commission opposes the deal. CSL, which makes blood plasma products, will repurchase as much as 9% of its stock for about $1.3 billion and pay Talecris $75 million for ending the offer.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC